Overview
Alternative Name 4-butoxy-N-[2-(4-hydroxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]benzamide
Lyophilized Powder yes
Source Synthetic
MW: 431.49
Purity: >96%
Effective concentration 100 µM.
Structure
Chemical name 4-butoxy-N-[2-(4-hydroxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]benzamide.
Molecular formula C25H25N3O4.
PubChem CID 11647668
Activity Quin-C7 is a nonpeptide antagonist of N-formyl peptide receptor 2 (FPR2, FPRL1), shown to partially displace [125I]WKYMVm from FPR2 receptors, and inhibit WKYMVm-induced calcium mobilization and chemotaxis at 100µM1.
References-Activity
- Zhou, C. et al. (2007) Mol. Pharmacol. 72, 976.
Shipping and storage Store at -20°C.
Solubility Soluble up to 100 mM in DMSO. Spin down all products before handling.
Storage of solutions Store at -20°C for several months. It is recommended to aliquot stock solutions to avoid repeated thawing and freezing.
Our bioassay
Alomone Labs Quin-C7 partially inhibits FPR2 activation in HL-60 cells.Non-differentiated HL-60 human acute promyelocytic leukemia cells were loaded with Fluo-3 AM. Changes in intracellular Ca2+ were detected as changes in Fluo-3 emission following stimulation. Normalized fluorescence is shown before and after application (arrow) of 10 nM FPR agonist WKYMVm (#GPW-105) in absence (top trace) or in presence of 100 µM Quin-C7 (#Q-155) (middle trace), compared to baseline (bottom trace).
Scientific background
Quin-C7 is a synthetic quinazolinone derivative that acts as a nonpeptide antagonist of human formyl peptide receptor like 1 (FPRL1, FPR2)1. Quin-C7 can partially displace [(125)I]Trp-Lys-Tyr-Met-Val-d-Met-NH(2) (WKYMVm) binding to FPRL1 receptor1.
The formyl peptide receptors include the FPR1, FPR2, and FPR3. FPR2 is primarily expressed in neutrophils and monocytes where it plays an important role in inflammation and in the immune system1,2.
Target FPR2 receptors
Lyophilized Powder
For research purposes only, not for human use
Last Update: 07/05/2024
Specifications
Citations
Citations
